Johnson & Johnson バランスシートの健全性 Johnson & Johnsonの総株主資本は$70.2B 、総負債は$35.8Bで、負債比率は51%となります。総資産と総負債はそれぞれ$178.3Bと$108.1Bです。 Johnson & Johnsonの EBIT は$23.1Bで、利息カバレッジ比率-35.9です。現金および短期投資は$20.3Bです。
主要情報 インタレスト・カバレッジ・レシオ -35.9x 現金 US$20.30b エクイティ US$70.16b 負債合計 US$108.13b 総資産 US$178.29b
財務の健全性に関する最新情報
すべての更新を表示 Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction Nov 14
Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease Nov 12
Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma Nov 08
Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya Oct 29
Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress Oct 26
Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis Oct 25
Third quarter dividend of US$1.24 announced Oct 21 Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson Oct 16
Third quarter 2024 earnings released: EPS: US$1.11 (vs US$1.71 in 3Q 2023) Oct 15 Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis Oct 10
Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide) Oct 03
Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned Oct 01
Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw) Sep 14
Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes Sep 11
Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025 Sep 06
Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis Aug 29
Johnson & Johnson Announces Executive Changes Aug 26
Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Aug 20
財務状況分析
短期負債: JNJの 短期資産 ( $53.2B ) が 短期負債 ( $51.8B ) を超えています。
長期負債: JNJの短期資産 ( $53.2B ) は 長期負債 ( $56.4B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: JNJの 純負債対資本比率 ( 22% ) は 満足できる 水準であると考えられます。
負債の削減: JNJの負債対資本比率は、過去 5 年間で50.2%から51%に増加しました。
債務返済能力: JNJの負債は 営業キャッシュフロー によって 十分にカバー されています ( 70.3% )。
インタレストカバレッジ: JNJ支払う利息よりも稼ぐ利息の方が多いので、 利息支払い の補償は問題になりません。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.